Close Menu

NEW YORK (GenomeWeb) – Sunnyvale, California-based InSilixa has received funding to develop a point-of-care rapid molecular diagnostic assay for oral human papillomavirus detection, the company announced today.

The $224,764 Phase I Small Business Innovation Research grant was awarded by the National Institutes of Health.

The assay is "a potential new tool to screen oral specimens such as saliva for cancer-causing HPV types and to risk stratify those persons found to be positive,” Gary Schoolnik, chief medical officer of InSilixa, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.